Posted by Michael Wonder on 12 Jan 2026
Encoded Therapeutics announces US FDA breakthrough therapy designation granted to ETX101 for the treatment of Dravet syndrome
12 January 2026 - Encoded Therapeutics today announced that the US FDA has granted breakthrough therapy designation to ETX101 for the treatment of SCN1A positive Dravet syndrome.
This designation is in addition to regenerative medicine advanced therapy, fast track, orphan drug and rare paediatric disease designations, all previously granted by the FDA.
